Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation
Company Announcements

Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation

Eiger Biopharmaceuticals (EIGR) has issued an announcement.

Eiger BioPharmaceuticals, Inc. has filed for Chapter 11 bankruptcy, leading to Nasdaq’s decision to delist the company’s stock due to non-compliance with listing rules. The company won’t appeal the delisting and anticipates its stock to commence trading on the over-the-counter market under the new symbol EIGRQ on April 11, 2024. Additionally, Dr. Jeffrey S. Glenn has resigned from the board, with no disputes influencing his departure.

For detailed information about EIGR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTwo option delistings on April 12th
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App